Protalix BioTherapeutics (PLX) Exchange Rate Effect (2010 - 2026)
Protalix BioTherapeutics (PLX) posted Exchange Rate Effect of $454000.0 for Q2 2026, up 689.61% on a QoQ basis from -$77000.0 in Q1 2026, and up 11250.0% year-over-year from N/an in Q2 2025.
Powered by 
Analysis
Protalix BioTherapeutics (PLX) Exchange Rate Effect (2010 - 2026) Analysis & Trends
Protalix BioTherapeutics has reported Exchange Rate Effect for 17 years, with the latest figure at $454000.0 in Q2 2026.
- On a quarterly basis, Exchange Rate Effect rose 11250.0% year-over-year to $454000.0 in Q2 2026; TTM through Jun 2026 was $334000.0, a 595.83% increase from a year earlier, with the FY2025 full-year figure at -$47000.0, down 288.0% from the prior year.
- Exchange Rate Effect was $454000.0 for Q2 2026 at Protalix BioTherapeutics, up from -$77000.0 in the prior quarter.
- The five-year high for Exchange Rate Effect was $454000.0 in Q2 2026, with the low at -$77000.0 in Q1 2026.
- Average Exchange Rate Effect over 5 years is $9647.1, with a median of -$12000.0 recorded in 2025.
- The sharpest annual moves came in 2022 and 2026: Exchange Rate Effect slumped 900.0% in 2022, then soared 11250.0% in 2026.
- Over 5 years, Exchange Rate Effect stood at -$26000.0 in 2022, then dropped by 3.85% to -$27000.0 in 2023, then soared by 300.0% to $54000.0 in 2024, then slumped by 157.41% to -$31000.0 in 2025, then jumped by 1564.52% to $454000.0 in 2026.
- The last three Exchange Rate Effect figures came in at $454000.0 (Q2 2026), -$77000.0 (Q1 2026), and -$31000.0 (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Exchange Rate Effect (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | - |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | -19.00 Mn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | -3.70 Mn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | -300,000.00 |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | - |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | -2.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | -2.45 Mn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | -3.40 Mn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | 315,000.00 |
| 10 | Protalix BioTherapeutics | 218.36 Mn | 177.71 Mn | 12.13 Mn | 454,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 454,000.00 |
| Mar 31, 2026 | -77,000.00 |
| Dec 31, 2025 | -31,000.00 |
| Sep 30, 2025 | -12,000.00 |
| Jun 30, 2025 | 4,000.00 |
| Mar 31, 2025 | -8,000.00 |
| Dec 31, 2024 | 54,000.00 |
| Sep 30, 2024 | -2,000.00 |
| Jun 30, 2024 | -20,000.00 |
| Mar 31, 2024 | -7,000.00 |
| Dec 31, 2023 | -27,000.00 |
| Sep 30, 2023 | -9,000.00 |
| Jun 30, 2023 | -36,000.00 |
| Mar 31, 2023 | -42,000.00 |
| Dec 31, 2022 | -26,000.00 |
| Jun 30, 2022 | -40,000.00 |
| Mar 31, 2022 | -11,000.00 |
| Dec 31, 2021 | 40,000.00 |
| Sep 30, 2021 | 1,000.00 |
| Jun 30, 2021 | -4,000.00 |